论文部分内容阅读
急性白血病的治疗近年来已取得一定的进展,疗效有一定的提高。1970年美国Sloan-Kettering研究院统计,当时急淋白血病病人生存5年以上者有159人,其中96人(60％)已活至8～20年而完全没有白血病的迹象。1972年法国巴黎白血病研究院报告490个急淋白血病病人,年龄在20岁以下者,初次治疗的完全缓解率为93.4％,中数缓解期超过3年,成人的缓解率为76.9％,中数生存期不到18月。1972年美国St.Jude医院的研究组根据10年间治疗急淋儿童的结果,预计不久的将来有50％病人可以获得长期缓解或治愈。目前治疗成人急粒白血病疗效最高者,缓解率大致为50～65％,中数缓解期一年左右。急粒的疗效虽尚远不及急淋,但与过去相比,疗效的提高也较显著。
In recent years, the treatment of acute leukemia has made some progress, and the curative effect is improved to a certain extent. In 1970, Sloan-Kettering Institute reported that there were 159 leukemia patients who survived for more than 5 years. 96 (60%) of them had lived to 8 to 20 years without any signs of leukemia at all. 1972 French Leukemia Institute of Paris 490 cases of acute leukemia patients under the age of 20, the initial treatment of complete remission was 93.4%, the median remission of more than 3 years, the adult remission rate was 76.9%, the median Survival of less than 18 months. In 1972, the research team of St. Jude Hospital in the United States based on the results of 10 years of treatment of acute child children, is expected in the near future, 50% of patients can obtain long-term relief or cure. The current treatment of acute myeloid leukemia most effective response rate was roughly 50 to 65%, the median remission of about one year. Although the efficacy of acute particles is far less than acute lymph node, but compared with the past, the effect is also more significant improvement.